All In Biotech

Drug Trial Radar · NCT03100500

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Apr 25, 2017

Primary completion

Jul 19, 2018

Study completion Feb 12, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 4, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.

Conditions

  • Asthma

Interventions

  • QMF149Drug

    QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 52 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Nagoya, Aichi-ken, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, Japan

  • Novartis Investigative Site

    Chitose, Hokkaido, Japan

  • Novartis Investigative Site

    Kitahiroshima, Hokkaido, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, Japan

  • Novartis Investigative Site

    Yokosuka, Kanagawa, Japan

  • Novartis Investigative Site

    Chino, Nagano, Japan

  • Novartis Investigative Site

    Higashiosaka, Osaka, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, Japan

  • Novartis Investigative Site

    Toshima-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.